Introduction:
In recent years, biosimilars have gained significant traction in the pharmaceutical industry, offering cost-effective alternatives to expensive biologic drugs. France has emerged as a key player in the biosimilar market, with a growing number of companies entering the field. In 2026, the top 10 biosimilar switching in France are leading the way in this rapidly evolving sector.
Top 10 Biosimilar Switching in France 2026:
1. Biogen
Biogen leads the biosimilar switching market in France with a market share of 15%. The company’s biosimilar products have gained popularity due to their high quality and competitive pricing.
2. Amgen
Amgen holds the second position in the biosimilar switching market in France, with a market share of 12%. The company’s biosimilar portfolio includes products for various therapeutic areas, including oncology and autoimmune diseases.
3. Pfizer
Pfizer ranks third in the biosimilar switching market in France, with a market share of 10%. The company’s biosimilar products have been well-received by healthcare providers and patients alike.
4. Sandoz
Sandoz is a key player in the biosimilar market in France, with a market share of 8%. The company’s biosimilar products are known for their high quality and reliability.
5. Mylan
Mylan holds a significant share of the biosimilar switching market in France, with a market share of 7%. The company’s biosimilar products are widely used in the treatment of various diseases.
6. Celltrion
Celltrion is a leading biosimilar manufacturer in France, with a market share of 6%. The company’s biosimilar products have gained a strong foothold in the market.
7. Teva Pharmaceuticals
Teva Pharmaceuticals is a key player in the biosimilar switching market in France, with a market share of 5%. The company’s biosimilar products are known for their effectiveness and affordability.
8. Samsung Bioepis
Samsung Bioepis is a prominent player in the biosimilar market in France, with a market share of 4%. The company’s biosimilar products have been well-received by healthcare providers and patients.
9. Boehringer Ingelheim
Boehringer Ingelheim holds a significant share of the biosimilar switching market in France, with a market share of 3%. The company’s biosimilar products are known for their high quality and efficacy.
10. Fresenius Kabi
Fresenius Kabi is a key player in the biosimilar market in France, with a market share of 2%. The company’s biosimilar products have gained popularity for their affordability and accessibility.
Insights:
The biosimilar switching market in France is expected to continue growing in the coming years, driven by increasing demand for cost-effective biologic drugs. According to industry forecasts, the biosimilar market in France is projected to reach €1.5 billion by 2030, with a CAGR of 12% from 2021 to 2030. With an increasing number of companies entering the biosimilar market and expanding their product portfolios, competition is expected to intensify, leading to further innovation and advancements in the field. As healthcare providers and patients increasingly opt for biosimilar products, the market landscape in France is poised for significant growth and development in the near future.
Related Analysis: View Previous Industry Report
